Article

IVI Research Brief Uses Insurance Value to Determine Long-Term Value of Therapies

A research brief from the Innovation and Value Initiative (IVI) looked at how the concept of insurance value can help stakeholders understand the value of therapies to the broader population.

A research brief from the Innovation and Value Initiative (IVI) looked at how the concept of insurance value can help stakeholders understand the value of therapies to the broader population. Insurance value measures the value that medical technologies offer healthy individuals by reducing the physical risks of possible illness, and the concept has been suggested as one of several elements to improve and enhance conventional cost-effecteness analysis.

The brief used IVI's Open-Source Value Platform mofel for rheumatoid arthritis (RA) to explore the application of insurance value because treatent of RA focuses on reducing impacts on quality of life rather than addressing mortality concerns.

Read the full research brief.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Andrew Kuykendall, MD, Moffitt Cancer Center
Merrill H. Stewart, MD
Dr Margrit Wiesendanger
David Awad, PharmD, BCOP
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Margrit Wiesendanger
Ibrahim Aldoss, MD, associate professor, City of Hope
Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida
Cathy Eng, MD, FACP, FASCO
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo